Levin Bruce R, Bull James J
Department of Biology, Emory University, Atlanta, Georgia 30307, USA.
Nat Rev Microbiol. 2004 Feb;2(2):166-73. doi: 10.1038/nrmicro822.
Following a sixty-year hiatus in western medicine, bacteriophages (phages) are again being advocated for treating and preventing bacterial infections. Are attempts to use phages for clinical and environmental applications more likely to succeed now than in the past? Will phage therapy and prophylaxis suffer the same fates as antibiotics--treatment failure due to acquired resistance and ever-increasing frequencies of resistant pathogens? Here, the population and evolutionary dynamics of bacterial-phage interactions that are relevant to phage therapy and prophylaxis are reviewed and illustrated with computer simulations.
在西医领域中断了六十年之后，噬菌体再次被提倡用于治疗和预防细菌感染。与过去相比，现在将噬菌体用于临床和环境应用的尝试更有可能成功吗？噬菌体疗法和预防措施会遭遇与抗生素相同的命运吗——即由于获得性耐药和耐药病原体频率不断增加而导致治疗失败？在此，回顾了与噬菌体疗法和预防相关的细菌-噬菌体相互作用的种群和进化动力学，并用计算机模拟进行了说明。
